Joel Lewis is Chief Executive Officer & President of Galectin Therapeutics Inc (GALT). The company reported total compensation of $1,189,674 for fiscal year 2024.
| Salary | $620,167 |
|---|---|
| Bonus | $312,000 |
| Stock awards | $202,635 |
| Option awards | — |
| Non-equity incentive plan | $54,872 |
| Pension and non-qualified deferred compensation | — |
| All other compensation | — |
| Total | $1,189,674 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Galectin Therapeutics Inc filed October 22, 2025, accession 0001140361-25-038875.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | Chief Executive Officer & President | $620,167 | $312,000 | $202,635 | — | $54,872 | — | — | $1,189,674 |
| FY2023 | Chief Executive Officer & President | $573,583 | $289,000 | $55,924 | — | $45,140 | — | — | $963,647 |
Totals as disclosed in each year's own compensation disclosure for Galectin Therapeutics Inc.
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Joel Lewis this page | Chief Executive Officer & President | $1,189,674 |
| Khurram Jamil, M.D. | Chief Medical Officer | $945,847 |
| Jack Callicutt | Chief Financial Officer | $716,945 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Galectin Therapeutics Inc compensation brief.
Joel Lewis's compensation sits inside Galectin Therapeutics Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.